AVBP - ArriVent BioPharma, Inc.

QQQ $ 617.50 $ 6.52 (1.07 %)

DIA $ 472.45 $ 4.92 (1.05 %)

SPY $ 677.25 $ 5.49 (0.82 %)

TLT $ 91.47 $ 0.04 (0.04 %)

GLD $ 378.59 $ -1.27 (-0.34 %)

Previous Close

$ 18.6

Open

$ 18.35

Bid

$ 12.00 x 30

Ask

$ 19.30 x 50

Day's Range

$ 18.16 - $ 18.84

52 Week Range

$ 15.47 - $ 36.37

Volume

292,538

Average Volume

Market Cap

Beta (5Y Monthly)

$ 1.17

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na (nm)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-11-2025	06-30-2025	10-Q
2	05-12-2025	03-31-2025	10-Q
3	03-03-2025	01-01-1970	10-K
4	11-14-2024	09-30-2024	10-Q
5	08-14-2024	06-30-2024	10-Q
6	05-08-2024	03-31-2024	10-Q
7	03-28-2024	12-31-2023	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

ArriVent BioPharma Presents Final Proof-Of...
09/09/2025 12:07:54

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in f...

HC Wainwright & Co. Maintains Buy on ArriV...
08/12/2025 12:14:11

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price targ...

Citigroup Maintains Buy on ArriVent BioPha...
08/12/2025 11:41:16

Citigroup analyst Yigal Nochomovitz maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $...

ArriVent BioPharma Q2 EPS $(0.90) Misses $...
08/11/2025 12:12:28

ArriVent BioPharma (NASDAQ:AVBP) reported quarterly losses of $(0.90) per share which missed the analyst consensus estimate of ...

HC Wainwright & Co. Reiterates Buy on Arri...
07/22/2025 10:29:38

HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $40 price ...

ArriVent Projects Topline Phase 3 FURVENT ...
07/21/2025 12:13:46

Enrollment in FURVENT was completed in Q1 2025Firmonertinib received FDA Breakthrough Therapy Designation in this patient popul...

Goldman Sachs Reinstates Buy on ArriVent B...
07/10/2025 18:13:57

Goldman Sachs analyst Corinne Johnson reinstates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and announces $33 price target.

centene-brightview-holdings-arrivent-biopharma-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session

Centene, BrightView Holdings, ArriVent Bio...
07/02/2025 12:22:29

Reported Earlier, ArriVent Biopharma Price...
07/02/2025 06:26:25

ArriVent Announces Proposed $75M Public Of...
07/01/2025 20:06:42

ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global deve...

Clear Street Initiates Coverage On ArriVen...
06/25/2025 17:26:29

Clear Street analyst Kaveri Pohlman initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces P...

Oppenheimer Maintains Outperform on ArriVe...
06/24/2025 14:03:52

Oppenheimer analyst Jeff Jones maintains ArriVent BioPharma (NASDAQ:AVBP) with a Outperform and raises the price target from...

Guggenheim Reiterates Buy on ArriVent BioP...
06/24/2025 12:38:24

Guggenheim analyst Michael Schmidt reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $45 price target.

ArriVent BioPharma Announces Additional Fo...
06/23/2025 11:17:13

16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in f...

Jones Trading Initiates Coverage On ArriVe...
05/20/2025 13:24:55

Jones Trading analyst Soumit Roy initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Pric...

HC Wainwright & Co. Maintains Buy on ArriV...
05/14/2025 17:29:08

HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and raises the price targ...

arrivent-lead-drug-candidate-shows-promise-in-lung-cancer-type-analyst-sees-over-50-upside

ArriVent Lead Drug Candidate Shows Promise...
03/20/2025 18:54:08

B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upsid...

B. Riley Securities Initiates Coverage On ...
03/20/2025 09:17:10

B. Riley Securities analyst Kalpit Patel initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announ...

Guggenheim Initiates Coverage On ArriVent ...
03/10/2025 14:58:07

Guggenheim analyst Michael Schmidt initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Pr...

HC Wainwright & Co. Reiterates Buy on Arri...
03/07/2025 12:35:45

HC Wainwright & Co. analyst Robert Burns reiterates ArriVent BioPharma (NASDAQ:AVBP) with a Buy and maintains $39 price ...